Galderma lance une étude clinique sur le Nemolizumab chez des adultes atteints de prurit chronique d'origine inconnue

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

NEMLUVIO® is a new and novel treatment for prurigo nodularis (PN) that offers fast itch relief in a convenient dosing.(1,2) Finally, a treatment for PN with less frequent doses than the other biologic.(1,3) 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. 2. Data on File: Continuous Treatment Group from PN Olympia 2 and LTE (REF-18414) 3. DUPIXENT. Prescribing Information. Sanofi Genzyme; 2023. Important Safety Informat

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years

Instagram

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults with Chronic Pruritus Of unknown Origin

Ask your dermatologist about NEMLUVIO® (nemolizumab-ilto), a treatment for adults with PN with a favorable safety profile, that relieves itch fast in as early as 48 hours with skin healing that lasts.(1,2*) Download this short discussion guide to help you get started. Important Safety Information Indication: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used to treat adults with prurigo nodularis. Contraindication: Known hypersensitivity to NEMLUVIO or any ingredients in NEMLUVIO. Warn

Galderma: ICD 2025: New data demonstrate Nemluvio's (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years